Class 4 Medicines Defect Notification: Baxter Healthcare Corporation, Onkotrone Injection 2 mg/ml concentrate for solution for infusion, EL(26)A/14
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 17 Mar 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Baxter Healthcare Corporation have informed the MHRA that the Patient Information Leaflet (PIL) packed in specified batches does not contain up to date information relating to the duration of contraception required for femal…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information
A%2F48/og.png)
Professional
Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48
...A of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12. mg” instead of “12.5Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F46/og.png)
Professional
Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46
Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines.
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F42/og.png)
Professional
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
Norgine Pharmaceuticals Limited is recalling the batches listed in the table due to risk of particulate matter being present in the product identified during routine stability investigations. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for.
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F44/og.png)
Professional
Class 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44
Advanz Pharma Limited are recalling specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of ....
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F41/og.png)
Professional
Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41
Norgine Limited is recalling specific batches of product as a precautionary measure due to some units containing the incorrect amounts of active ingredients. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)
%2C%20EL(26)A%2F43/og.png)
Professional
Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43
...med MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrelRead the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
17 Mar 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
- Class 2 Medicines Recall: Baxter Healthcare Limited, Compound Sodium Lactate Solution for Infusion BP (Hartmann's Solution for infusion) in Viaflo 1000ml, EL(25)A/46
- Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
- Class 4 Medicines Defect Notification: Hikma Farmacêutica, Gemcitabine 2g/52.6ml concentrate for solution for infusion, EL(25)A/43
- Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
- Class 4 Medicines Defect Notification: Viatris Products Ltd, Arixtra solution for injection, pre-filled syringes, EL(26)A/04
- Dräger Atlan Anaesthesia workstations: risk of ventilator failure (DSI/2026/005)
- Field Safety Notices: 1 May 2026
- Field Safety Notices: 02-06 February 2026
- Field Safety Notices: 09-13 February 2026
- Field Safety Notices: 11 to 15 August 2025
- Field Safety Notices: 17 to 21 November 2025
- Field Safety Notices: 18 -22 May 2026
- Field Safety Notices: 23-27 March 2026
- Field Safety Notices: 24 to 28 November 2025
- Field Safety Notices: 27 to 31 July 2026
- Field Safety Notices: 29 June to 03 July 2026
- Field Safety Notices: 29 September to 3 October 2025
- Field Safety Notices: 30 March - 3 April 2026
- Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error


